Cipla stock slides after FDA action on lanreotide 2026

Market reaction: Cipla stock comes under pressure

Cipla shares traded lower after the company disclosed that the US Food and Drug Administration (US FDA) issued an “official action indicated” (OAI) status to Pharmathen International S.A. Pharmathen supplies lanreotide injection to Cipla USA, a wholly-owned subsidiary. In one trading session referenced in the reports, Cipla fell over 2% to an intraday low of INR 1,308.80. Separately, other reports described sharper single-day declines around earlier updates linked to the same supply chain issue. The immediate trigger across these instances was regulatory action at a third-party facility in Greece that supports Cipla’s US supply of a key complex injectable.

What the US FDA action relates to

The US FDA conducted a current good manufacturing practices (cGMP) inspection at Pharmathen International’s manufacturing facility at Rodopi, Greece, in November. Another report specified that the inspection at the Rodopi site ran from Nov. 10, 2025 to Nov. 21, 2025. Following the inspection, the regulator issued nine Form 483 observations, according to media reports cited in the provided text. These observations flagged concerns including contamination risks, aseptic process deficiencies, and potential data integrity issues. While Form 483 observations do not, by themselves, represent a final enforcement decision, Cipla later disclosed that the outcome for the site was an OAI status.

Why lanreotide is central to the story

Lanreotide is among Cipla’s most important products in the US portfolio and is supplied through Pharmathen. Cipla has described Pharmathen as the exclusive supplier of lanreotide injection to Cipla USA for the US market. The product’s exposure is meaningful: lanreotide accounted for nearly 12% of Cipla’s sales in the US in 2025, as per the Informist report in the prompt. Another report also noted the product commands a market share of 22%.

This matters because a disruption in a single-source, complex injectable can quickly translate into lost sales and weaker profitability, especially if replenishment timelines shift. Cipla has also linked the issue to a wider set of near-term pressures in the US business, including the expected lack of certain product sales in a specific quarter.

Production pause and supply constraints

Pharmathen had already paused lanreotide production after the US regulator’s observations in November, according to the Informist item. Cipla later reiterated in an exchange filing that supply of lanreotide injection would remain constrained in the near term after its exclusive partner temporarily paused production following inspectional observations by the US FDA. The company has said it is in discussions with Pharmathen, is monitoring developments, and is working with its partner to restore supplies.

Cipla’s management has also outlined mitigation steps. At a post-earnings press conference cited in the prompt, management said Cipla is exploring multiple options, including alternative production sites, to reduce supply risk for the hormone and tumour drug.

Guidance cuts: margins reset as disruption persists

Cipla has already reflected the ongoing lanreotide disruption in its profitability guidance. The company on Jan. 23 lowered its 2025-26 (Apr-Mar) EBITDA margin guidance to 21.00% from 22.75% earlier, citing a persistent lanreotide supply issue, according to the Informist report. Another report in the prompt described this as the second reduction, from an earlier projection of 22.5% to 21% for the ongoing financial year.

Cipla has also indicated that a specific quarter would remain challenging, with no expected sales of generic Revlimid or lanreotide during that period, as per the India Blooms report excerpt provided.

What brokerages are saying

Brokerage views in the provided text show a wide dispersion on duration and financial impact, but the near-term risk is consistently linked to lanreotide supply. Jefferies retained an ‘underperform’ rating and highlighted meaningful downside risk from supply woes, with expectations that the issues could extend into FY28, according to a social media post referenced by NDTV Profit. This contrasts with Cipla management’s earlier commentary that lanreotide supply will resume in the first half of FY27.

Other brokerages cited include Morgan Stanley, which trimmed its price target to INR 1,292 and cut its earnings growth estimate by 2% for fiscal 2025-26 and 1% for 2026-27, pointing to potential market share loss if disruption is prolonged. Nuvama Institutional Equities downgraded Cipla to ‘reduce’ from ‘hold’, cut FY27E EPS by 11%, and revised its target price to INR 1,360 from INR 1,715. Nomura, on the other hand, maintained a ‘buy’ rating with a target price of INR 1,770, saying the potential loss of lanreotide sales has largely been priced in, as cited in the prompt.

Cipla’s US business context: exposure and sensitivity

The US remains a critical geography for Cipla. One report stated the US market contributed 27% of Cipla’s topline in FY2024-25, with record sales of USD 934 million. The same text also reported US sales of USD 233 million for the September 2025 quarter.

Because lanreotide is a high-value complex injectable and a top US product for Cipla, supply interruptions can have an outsized effect on quarterly numbers and margin trajectory. A brokerage note cited in the prompt (ICICI Securities) estimated lanreotide could contribute 5-7% to overall revenues and 8-9% to EBITDA for FY27, highlighting the sensitivity of profitability to the product’s availability.

Key facts at a glance

Market impact: what changed for investors

The disclosures affected Cipla’s stock price across multiple trading sessions cited in the prompt. The immediate market concern is that constrained supply could persist longer than management’s initial resumption timeline, and that remediation could introduce further uncertainty. Investors also weighed the downside from the phasing out of generic Revlimid and the possibility of competitive intensity in other US products, as discussed in the brokerage commentary included.

Brokerage positioning reflects this uncertainty. Informist data in the prompt showed that out of 12 brokerage reports available on Cipla, eight had an average target price of INR 1,560, while three had a ‘sell’ call and one brokerage said ‘hold’.

Analysis: why this event matters beyond one product

The lanreotide episode highlights a recurring risk for Indian pharma companies scaling complex injectables in the US: reliance on specialised third-party manufacturing sites and the regulatory scrutiny that comes with sterile production. Even when observations relate to a partner site rather than the company’s own plants, supply chains can tighten quickly if a single-source product faces compliance remediation.

For Cipla specifically, the key variables in the provided reports are the remediation pace at Pharmathen, the feasibility and timing of shifting to alternative production sites, and the duration of constrained supply. The company’s prior guidance cut to 21% EBITDA margin indicates that disruption has already been material enough to change financial expectations.

Conclusion: watch the remediation timeline and resupply updates

Cipla’s disclosures around the US FDA’s OAI status for Pharmathen have kept attention focused on lanreotide supply continuity and the company’s US earnings sensitivity. Management has said it is exploring alternative production sites to reduce supply risk, while earlier guidance suggested resupply in the first half of FY27. The next key updates are likely to come through further exchange filings, partner remediation milestones, and any revision to supply restoration timelines already communicated to the market.